Cataract Clinical Trial
Official title:
The Effect of Eye Exercises for the Stimulation of Neuroadaptation After Multifocal Intraocular Lens Implantation on Visual Function and Quality of Life
The goal of this clinical trial is to examine the effects of eye exercises on visual function and quality of life in cataract patients undergoing multifocal intraocular lens implantation. The main questions it aims to answer are: - Does it improve visual functions? - Does it improve vision-related quality of life? Participants in the intervention group will perform 8-step eye exercises at least once a day for 12 weeks. The control group will not practice, they will only be evaluated.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2024 |
Est. primary completion date | December 25, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Individuals who can read, - To adapt to the training program, - To be involved in working voluntarily, Exclusion Criteria: - Individuals with a history of eye surgery, - Being diagnosed with strabismus, - Being diagnosed with glaucoma, - Having a history of neurological disease that will affect vision and eye muscles, - Having retinal and visual pathway damage, - Having functional damage that will prevent the practice of exercises. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Idris Dogan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Demographic information | name, surname, contact information, age, weight, height, occupation, education level, CV, family history, medication, etc. | Only on the first assessment (through study completion, an average of 12 week) | |
Other | anxiety level (State Trait Anxiety Inventory I-II) | The response options collected in four classes in the state anxiety scale are (1) Not at all, (2) A little, (3) A lot, and (4) Completely; The options in the Trait Anxiety Scale are (1) Almost never, (2) Sometimes, (3) Often, and (4) Almost always. There are two kinds of expressions in the scales. We can call these (1) direct or straight statements and (2) inverted statements. Direct expressions, negative emotions; reversed expressions express positive emotions. When scoring this second type of statements, those with a weight of 1 turn into 4, and those with a weight of 4 turn into 1. In direct statements, answers with a value of 4 indicate high anxiety. In reversed statements, answers with a value of 1 indicate high anxiety, and those with a value of 4 indicate low anxiety. The scores obtained from both scales theoretically vary between 20 and 80. A large score indicates a high level of anxiety, and a small score indicates a low level of anxiety. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Other | cognitive performance | Standardized Mini Mental Test will be used. | Only on the first assessment (through study completion, an average of 12 week) | |
Primary | Contrast Sensitivity | The Pelli-Robson contrast sensitivity test is a wall chart measuring 90 X 60 cm. The chart comprises 8 lines of letters with different contrasts. Each line has 6 letters; the first 3 letters (a triplet) on the left have more contrast than the 3 letters on the right. The contrast also decreases downward from line to line. The size of the letters is 4.9 X 4.9 cm. There are different sets of letters on each side of the chart. It recommends a test distance of 1 m. The logarithmic contrast sensitivity value of the last triplet of which at least 2 letters are correctly seen is marked as the result. The luminance of the test should be 85 candelas/m2 (cd/m2 ); the accepted range is 60 to 120 cd/m2. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Primary | Visual acuity | Snellen chart will be used for visual acuity measurement. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Primary | Vision-related quality of life | The National Institute of Eye Health Visual Function Scale (NEI-VFQ-25) will be used. This scale is used to evaluate visual function loss due to eye diseases and was developed by Mangione et al. in 1988. In order to make this scale, whose original form consists of 51 questions, more useful, a 25-question form was developed. The short form of 25 questions consists of 3 parts. These sections are respectively; general health and vision, difficulties with activities, and the consequences of vision problems. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Secondary | Refraction errors | The refraction defects were measured by autorefractometry, which is frequently used because it provides fast and reliable results in clinic. In the autorefractometry method, the infrared rays sent to the patient's eye are reflected from the retina back to the device and evaluate the refraction defect of the patient | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Secondary | Intraocular Pressure | It will be measured with the Reichert 7CR Automatic Non Contact Tonometer device. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Secondary | Pupillary diameter | will be evaluated using optical biometry. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) | |
Secondary | Reading speed | Written material prepared in Times New Roman font and 12 point size will be read to the participant for one minute under appropriate lighting. At the end of the one-minute reading period, correctly read and incorrectly read words will be counted. The numerical value obtained by subtracting the number of words read incorrectly from the number of words read correctly will be used as a measure of the participant's reading speed. | 12 Week (3 times in total, before the operation, at the 1st and 3rd months after the operation.) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |